GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
Ted W. Love, M.D.Location
UpGuard's CSTAR Score ranges from 0 to 950. The higher the score, the more effective a company is in implementing good security practices.
Book a call with one of our specialists and we'll arrange a time for a demo.